Lv3
222 积分 2023-09-26 加入
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
6天前
已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
6天前
已完结
Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort
6天前
已完结
Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype
24天前
已完结
Toripalimab vs Dacarbazine as First-Line Therapy for Advanced Melanoma of Acral Subtype
25天前
已完结
The immune modifying effects of chemotherapy and advances in chemo-immunotherapy
28天前
已完结
The immune modifying effects of chemotherapy and advances in chemo-immunotherapy
1个月前
已完结
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial
1个月前
已完结
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial
2个月前
已完结
The Economic Burden of Recurrence in Triple-Negative Breast Cancer Among Working Age Patients in the United States
2个月前
已完结
皖公网安备34019202002308
